News

Series D Capital Raise Complete Total amount raised surpasses 7.3 billion JPY

Innovacell Publishes Sponsored Articles by Leading Physicians (Regarding Fecal Incontinence Treatment)

Approximately 400 million yen was raised from publicly offered investment trusts managed by Rheos Capital Works

Innovacell raised a total of 1.06 billion yen through FUNDINNO PLUS+

Innovacell has established a capital and business alliance with Alfresa Corporation with an investment of 1 billion yen and has signed a basic business partnership agreement for the sales of the flagship product ICEF15.

The CEO and COO of Innovacell K.K. will speak at the 4th SBI Bio Conference, the 26th Interphex Week, and the 6th Regenerative Medicine EXPO.

The administration of the first patient in the Phase III trial of autologous skeletal muscle-derived cells (ICEF15) for the treatment of fecal incontinence has been completed.

Innovacell will be featured in the Nikkei BP Bio-Healthcare Startup Overview 2023-2024.

The CEO and COO of Innovacell Inc. will present at the 30th CITIC CLSA Investors’ Forum.

First patient enrolled in Japan for the Phase III trial of autologous skeletal muscle-derived cells (ICEF15) targeting fecal incontinence.